MarketInOut Stock Screener Log In | Sign Up
 

UCB S.A. ADR

OTC • Healthcare • Biotechnology • Quote as of 08/13/2026 11:59
UCB S.A. ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization48,967 mln
Float240 mln
Earnings Date02/25/2027

EPS

6.49
Strong

P / E

19.62
Moderately valued

Piotroski F-Score

9 / 9
Exceptional

Beneish M-Score

-2.49
Borderline

1-Year Forecast

164
Strong upside

Relative Strength

43 / 100
Slightly lagging

Business Description

UCB SA is a Belgian biopharmaceutical company founded in 1925 and headquartered in Brussels, focused on developing medicines for people living with neurological and immune system conditions. Its portfolio includes established treatments for epilepsy, Parkinson's disease, rheumatoid arthritis, psoriasis, and osteoporosis, among other serious conditions. The company is also advancing a pipeline of new therapies targeting Alzheimer's disease, lupus, and several rare genetic disorders. In addition to its research and commercial activities, UCB provides contract manufacturing services.

Key Fundamentals

EPS6.49
P/E19.62
ROE20.48
RPS25.55
ROIC17.09
ROA11.79
Interest Cover29.19
EBITDA, mln3,777
EV / EBITDA12.88
EV / EBIT15.95
Revenue, mln9,901
EV / Revenue4.91

Financial Strength

Altman Z-Score5.41
Piotroski F-Score 9 / 9
Beneish M-Score-2.49
Price to Lynch Fair Value2.27
Price to Graham Number9.15
1-Year Target Price164
Shiller PE Ratio33.73

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.39% 24 / 100   
1 Month -6.75% 21 / 100   
2 Months -8.73% 38 / 100   
6 Months -19.22% 31 / 100   
1 Year 15.98% 55 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us